{"id":59184,"date":"2026-03-10T16:28:50","date_gmt":"2026-03-10T08:28:50","guid":{"rendered":"https:\/\/flcube.com\/?p=59184"},"modified":"2026-03-10T16:28:51","modified_gmt":"2026-03-10T08:28:51","slug":"qyuns-therapeutics-qx002n-nda-accepted-by-nmpa-il-17a-antibody-targets-ankylosing-spondylitis-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59184","title":{"rendered":"Qyuns Therapeutics&#8217; QX002N NDA Accepted by NMPA \u2013 IL-17A Antibody Targets Ankylosing Spondylitis Market"},"content":{"rendered":"\n<p><strong>Qyuns Therapeutics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2509:HKG\">HKG: 2509<\/a>) announced that the <strong>New Drug Application (NDA)<\/strong> for <strong>QX002N<\/strong>, its <strong>first innovative drug<\/strong>, has been <strong>officially accepted<\/strong> by China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> (Acceptance No.: CXSS2600039) for the treatment of <strong>active ankylosing spondylitis (AS)<\/strong> in adults. The <strong>high-affinity IL-17A monoclonal antibody<\/strong>, independently developed by Qyuns, positions the company to enter the <strong>competitive autoimmune market<\/strong> with a <strong>biosimilar-like innovator<\/strong> targeting the <strong>validated IL-17 pathway<\/strong> that drives axial spondyloarthritis pathogenesis.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Filing Type<\/strong><\/td><td>New Drug Application (NDA)<\/td><\/tr><tr><td><strong>Acceptance Number<\/strong><\/td><td>CXSS2600039<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>QX002N<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>High-affinity monoclonal antibody targeting IL-17A<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Active ankylosing spondylitis (AS) in adults<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Qyuns Therapeutics (HKG: 2509)<\/td><\/tr><tr><td><strong>Milestone<\/strong><\/td><td>First innovative drug NDA for Qyuns<\/td><\/tr><tr><td><strong>Acceptance Date<\/strong><\/td><td>10\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>QX002N Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Target<\/strong><\/td><td>Interleukin-17A (IL-17A) \u2013 including both IL-17AA and IL-17AF homodimers\/heterodimers<\/td><\/tr><tr><td><strong>Binding Affinity<\/strong><\/td><td>High-affinity monoclonal antibody<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Blocks IL-17A interaction with IL-17 receptor \u2192 inhibits pro-inflammatory cytokine release<\/td><\/tr><tr><td><strong>Pathophysiological Role<\/strong><\/td><td>\u2022 Induces pro-inflammatory cytokines<br>\u2022 Regulates bone metabolism<br>\u2022 Primary driver of AS pathogenesis (enthesitis, bone erosion, new bone formation)<\/td><\/tr><tr><td><strong>Clinical Outcome<\/strong><\/td><td>Slows disease progression; reduces spinal inflammation and structural damage<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Market Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>China AS Prevalence<\/strong><\/td><td>~5 million patients; underdiagnosis common; biologic penetration &lt;10% vs. 30%+ in Western markets<\/td><\/tr><tr><td><strong>Standard of Care Evolution<\/strong><\/td><td>NSAIDs \u2192 TNF inhibitors (adalimumab) \u2192 IL-17A inhibitors (secukinumab, ixekizumab) as second-line<\/td><\/tr><tr><td><strong>IL-17A Class Validation<\/strong><\/td><td>Secukinumab (Novartis) and ixekizumab (Eli Lilly) established efficacy in AS; QX002N follows validated mechanism<\/td><\/tr><tr><td><strong>Qyuns Positioning<\/strong><\/td><td>Domestic innovator with potential cost advantage vs. multinational originators<\/td><\/tr><tr><td><strong>Pricing Pressure<\/strong><\/td><td>NRDL negotiation anticipated; biosimilar competition emerging for reference products<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-dynamics\">Competitive Dynamics<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>China Status<\/th><th>QX002N Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Novartis<\/strong><\/td><td>Cosentyx (secukinumab)<\/td><td>IL-17A inhibitor<\/td><td>Approved (AS)<\/td><td>First-to-class; established market presence<\/td><\/tr><tr><td><strong>Eli Lilly<\/strong><\/td><td>Taltz (ixekizumab)<\/td><td>IL-17A inhibitor<\/td><td>Approved (AS)<\/td><td>Strong efficacy data; pediatric expansion<\/td><\/tr><tr><td><strong>AbbVie<\/strong><\/td><td>Humira (adalimumab)<\/td><td>TNF inhibitor<\/td><td>Approved (AS); biosimilars available<\/td><td>Earlier line positioning; IL-17A for TNF failures<\/td><\/tr><tr><td><strong>Qyuns<\/strong><\/td><td><strong>QX002N<\/strong><\/td><td><strong>IL-17A inhibitor<\/strong><\/td><td><strong>NDA accepted<\/strong><\/td><td><strong>China-developed; potential manufacturing cost advantage; local commercial infrastructure<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-outlook\">Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Timeline<\/th><th>Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>NDA Review<\/strong><\/td><td>2026-2027<\/td><td>NMPA technical review; clinical site inspection; manufacturing audit<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>Q4 2026 \u2013 Q1 2027<\/td><td>Conditional or full approval anticipated<\/td><\/tr><tr><td><strong>Commercial Launch<\/strong><\/td><td>2027<\/td><td>Hospital formulary access; rheumatologist education; patient identification<\/td><\/tr><tr><td><strong>NRDL Negotiation<\/strong><\/td><td>2027-2028<\/td><td>National reimbursement list inclusion critical for volume expansion<\/td><\/tr><tr><td><strong>Pipeline Expansion<\/strong><\/td><td>Ongoing<\/td><td>Psoriasis, psoriatic arthritis potential indications<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding NDA review timelines, regulatory approval, and commercial positioning for QX002N. Actual results may differ due to NMPA review delays, competitive dynamics with established IL-17A inhibitors, and pricing negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Qyuns Therapeutics (HKG: 2509) announced that the New Drug Application (NDA) for QX002N, its first&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,1239,38],"class_list":["post-59184","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-hkg-2509","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Qyuns Therapeutics&#039; QX002N NDA Accepted by NMPA \u2013 IL-17A Antibody Targets Ankylosing Spondylitis Market - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Qyuns Therapeutics (HKG: 2509) announced that the New Drug Application (NDA) for QX002N, its first innovative drug, has been officially accepted by China&#039;s National Medical Products Administration (NMPA) (Acceptance No.: CXSS2600039) for the treatment of active ankylosing spondylitis (AS) in adults. The high-affinity IL-17A monoclonal antibody, independently developed by Qyuns, positions the company to enter the competitive autoimmune market with a biosimilar-like innovator targeting the validated IL-17 pathway that drives axial spondyloarthritis pathogenesis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59184\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Qyuns Therapeutics&#039; QX002N NDA Accepted by NMPA \u2013 IL-17A Antibody Targets Ankylosing Spondylitis Market\" \/>\n<meta property=\"og:description\" content=\"Qyuns Therapeutics (HKG: 2509) announced that the New Drug Application (NDA) for QX002N, its first innovative drug, has been officially accepted by China&#039;s National Medical Products Administration (NMPA) (Acceptance No.: CXSS2600039) for the treatment of active ankylosing spondylitis (AS) in adults. The high-affinity IL-17A monoclonal antibody, independently developed by Qyuns, positions the company to enter the competitive autoimmune market with a biosimilar-like innovator targeting the validated IL-17 pathway that drives axial spondyloarthritis pathogenesis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59184\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-10T08:28:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-10T08:28:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59184#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59184\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Qyuns Therapeutics&#8217; QX002N NDA Accepted by NMPA \u2013 IL-17A Antibody Targets Ankylosing Spondylitis Market\",\"datePublished\":\"2026-03-10T08:28:50+00:00\",\"dateModified\":\"2026-03-10T08:28:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59184\"},\"wordCount\":453,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"HKG: 2509\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59184#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59184\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59184\",\"name\":\"Qyuns Therapeutics' QX002N NDA Accepted by NMPA \u2013 IL-17A Antibody Targets Ankylosing Spondylitis Market - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-10T08:28:50+00:00\",\"dateModified\":\"2026-03-10T08:28:51+00:00\",\"description\":\"Qyuns Therapeutics (HKG: 2509) announced that the New Drug Application (NDA) for QX002N, its first innovative drug, has been officially accepted by China's National Medical Products Administration (NMPA) (Acceptance No.: CXSS2600039) for the treatment of active ankylosing spondylitis (AS) in adults. The high-affinity IL-17A monoclonal antibody, independently developed by Qyuns, positions the company to enter the competitive autoimmune market with a biosimilar-like innovator targeting the validated IL-17 pathway that drives axial spondyloarthritis pathogenesis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59184#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59184\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59184#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Qyuns Therapeutics&#8217; QX002N NDA Accepted by NMPA \u2013 IL-17A Antibody Targets Ankylosing Spondylitis Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Qyuns Therapeutics' QX002N NDA Accepted by NMPA \u2013 IL-17A Antibody Targets Ankylosing Spondylitis Market - Insight, China&#039;s Pharmaceutical Industry","description":"Qyuns Therapeutics (HKG: 2509) announced that the New Drug Application (NDA) for QX002N, its first innovative drug, has been officially accepted by China's National Medical Products Administration (NMPA) (Acceptance No.: CXSS2600039) for the treatment of active ankylosing spondylitis (AS) in adults. The high-affinity IL-17A monoclonal antibody, independently developed by Qyuns, positions the company to enter the competitive autoimmune market with a biosimilar-like innovator targeting the validated IL-17 pathway that drives axial spondyloarthritis pathogenesis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59184","og_locale":"en_US","og_type":"article","og_title":"Qyuns Therapeutics' QX002N NDA Accepted by NMPA \u2013 IL-17A Antibody Targets Ankylosing Spondylitis Market","og_description":"Qyuns Therapeutics (HKG: 2509) announced that the New Drug Application (NDA) for QX002N, its first innovative drug, has been officially accepted by China's National Medical Products Administration (NMPA) (Acceptance No.: CXSS2600039) for the treatment of active ankylosing spondylitis (AS) in adults. The high-affinity IL-17A monoclonal antibody, independently developed by Qyuns, positions the company to enter the competitive autoimmune market with a biosimilar-like innovator targeting the validated IL-17 pathway that drives axial spondyloarthritis pathogenesis.","og_url":"https:\/\/flcube.com\/?p=59184","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-10T08:28:50+00:00","article_modified_time":"2026-03-10T08:28:51+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59184#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59184"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Qyuns Therapeutics&#8217; QX002N NDA Accepted by NMPA \u2013 IL-17A Antibody Targets Ankylosing Spondylitis Market","datePublished":"2026-03-10T08:28:50+00:00","dateModified":"2026-03-10T08:28:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59184"},"wordCount":453,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","HKG: 2509","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59184#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59184","url":"https:\/\/flcube.com\/?p=59184","name":"Qyuns Therapeutics' QX002N NDA Accepted by NMPA \u2013 IL-17A Antibody Targets Ankylosing Spondylitis Market - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-10T08:28:50+00:00","dateModified":"2026-03-10T08:28:51+00:00","description":"Qyuns Therapeutics (HKG: 2509) announced that the New Drug Application (NDA) for QX002N, its first innovative drug, has been officially accepted by China's National Medical Products Administration (NMPA) (Acceptance No.: CXSS2600039) for the treatment of active ankylosing spondylitis (AS) in adults. The high-affinity IL-17A monoclonal antibody, independently developed by Qyuns, positions the company to enter the competitive autoimmune market with a biosimilar-like innovator targeting the validated IL-17 pathway that drives axial spondyloarthritis pathogenesis.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59184#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59184"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59184#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Qyuns Therapeutics&#8217; QX002N NDA Accepted by NMPA \u2013 IL-17A Antibody Targets Ankylosing Spondylitis Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59184"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59184\/revisions"}],"predecessor-version":[{"id":59185,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59184\/revisions\/59185"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}